Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer

Shigeru Hashimoto, Shuji Mikami, Hirokazu Sugino, Ayumu Yoshikawa, Ari Hashimoto, Yasuhito Onodera, Shotaro Furukawa, Haruka Handa, Tsukasa Oikawa, Yasunori Okada, Mototsugu Oya, Hisataka Sabe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Acquisition of mesenchymal properties by cancer cells is critical for their malignant behaviour, but regulators of the mesenchymal molecular machinery and how it is activated remain elusive. Here we show that clear cell renal cell carcinomas (ccRCCs) frequently utilize the Arf6-based mesenchymal pathway to promote invasion and metastasis, similar to breast cancers. In breast cancer cells, ligand-activated receptor tyrosine kinases employ GEP100 to activate Arf6, which then recruits AMAP1; and AMAP1 then binds to the mesenchymal-specific protein EPB41L5, which promotes epithelial-mesenchymal transition and focal adhesion dynamics. In renal cancer cells, lysophosphatidic acid (LPA) activates Arf6 via its G-protein-coupled receptors, in which GTP-Gα12 binds to EFA6. The Arf6-based pathway may also contribute to drug resistance. Our results identify a specific mesenchymal molecular machinery of primary ccRCCs, which is triggered by a product of autotaxin and it is associated with poor outcome of patients.

Original languageEnglish
Article number10656
JournalNature Communications
Volume7
DOIs
Publication statusPublished - 2016 Feb 8

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
cancer
Cells
acids
Breast Neoplasms
Machinery
Neoplasms
Focal Adhesions
Epithelial-Mesenchymal Transition
machinery
Receptor Protein-Tyrosine Kinases
G-Protein-Coupled Receptors
Guanosine Triphosphate
Drug Resistance
breast
Neoplasm Metastasis
Ligands
proteins
Adhesion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Hashimoto, S., Mikami, S., Sugino, H., Yoshikawa, A., Hashimoto, A., Onodera, Y., ... Sabe, H. (2016). Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nature Communications, 7, [10656]. https://doi.org/10.1038/ncomms10656

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. / Hashimoto, Shigeru; Mikami, Shuji; Sugino, Hirokazu; Yoshikawa, Ayumu; Hashimoto, Ari; Onodera, Yasuhito; Furukawa, Shotaro; Handa, Haruka; Oikawa, Tsukasa; Okada, Yasunori; Oya, Mototsugu; Sabe, Hisataka.

In: Nature Communications, Vol. 7, 10656, 08.02.2016.

Research output: Contribution to journalArticle

Hashimoto, S, Mikami, S, Sugino, H, Yoshikawa, A, Hashimoto, A, Onodera, Y, Furukawa, S, Handa, H, Oikawa, T, Okada, Y, Oya, M & Sabe, H 2016, 'Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer', Nature Communications, vol. 7, 10656. https://doi.org/10.1038/ncomms10656
Hashimoto, Shigeru ; Mikami, Shuji ; Sugino, Hirokazu ; Yoshikawa, Ayumu ; Hashimoto, Ari ; Onodera, Yasuhito ; Furukawa, Shotaro ; Handa, Haruka ; Oikawa, Tsukasa ; Okada, Yasunori ; Oya, Mototsugu ; Sabe, Hisataka. / Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. In: Nature Communications. 2016 ; Vol. 7.
@article{393f527f178f4d44bd455ab6f47ebbdb,
title = "Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer",
abstract = "Acquisition of mesenchymal properties by cancer cells is critical for their malignant behaviour, but regulators of the mesenchymal molecular machinery and how it is activated remain elusive. Here we show that clear cell renal cell carcinomas (ccRCCs) frequently utilize the Arf6-based mesenchymal pathway to promote invasion and metastasis, similar to breast cancers. In breast cancer cells, ligand-activated receptor tyrosine kinases employ GEP100 to activate Arf6, which then recruits AMAP1; and AMAP1 then binds to the mesenchymal-specific protein EPB41L5, which promotes epithelial-mesenchymal transition and focal adhesion dynamics. In renal cancer cells, lysophosphatidic acid (LPA) activates Arf6 via its G-protein-coupled receptors, in which GTP-Gα12 binds to EFA6. The Arf6-based pathway may also contribute to drug resistance. Our results identify a specific mesenchymal molecular machinery of primary ccRCCs, which is triggered by a product of autotaxin and it is associated with poor outcome of patients.",
author = "Shigeru Hashimoto and Shuji Mikami and Hirokazu Sugino and Ayumu Yoshikawa and Ari Hashimoto and Yasuhito Onodera and Shotaro Furukawa and Haruka Handa and Tsukasa Oikawa and Yasunori Okada and Mototsugu Oya and Hisataka Sabe",
year = "2016",
month = "2",
day = "8",
doi = "10.1038/ncomms10656",
language = "English",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer

AU - Hashimoto, Shigeru

AU - Mikami, Shuji

AU - Sugino, Hirokazu

AU - Yoshikawa, Ayumu

AU - Hashimoto, Ari

AU - Onodera, Yasuhito

AU - Furukawa, Shotaro

AU - Handa, Haruka

AU - Oikawa, Tsukasa

AU - Okada, Yasunori

AU - Oya, Mototsugu

AU - Sabe, Hisataka

PY - 2016/2/8

Y1 - 2016/2/8

N2 - Acquisition of mesenchymal properties by cancer cells is critical for their malignant behaviour, but regulators of the mesenchymal molecular machinery and how it is activated remain elusive. Here we show that clear cell renal cell carcinomas (ccRCCs) frequently utilize the Arf6-based mesenchymal pathway to promote invasion and metastasis, similar to breast cancers. In breast cancer cells, ligand-activated receptor tyrosine kinases employ GEP100 to activate Arf6, which then recruits AMAP1; and AMAP1 then binds to the mesenchymal-specific protein EPB41L5, which promotes epithelial-mesenchymal transition and focal adhesion dynamics. In renal cancer cells, lysophosphatidic acid (LPA) activates Arf6 via its G-protein-coupled receptors, in which GTP-Gα12 binds to EFA6. The Arf6-based pathway may also contribute to drug resistance. Our results identify a specific mesenchymal molecular machinery of primary ccRCCs, which is triggered by a product of autotaxin and it is associated with poor outcome of patients.

AB - Acquisition of mesenchymal properties by cancer cells is critical for their malignant behaviour, but regulators of the mesenchymal molecular machinery and how it is activated remain elusive. Here we show that clear cell renal cell carcinomas (ccRCCs) frequently utilize the Arf6-based mesenchymal pathway to promote invasion and metastasis, similar to breast cancers. In breast cancer cells, ligand-activated receptor tyrosine kinases employ GEP100 to activate Arf6, which then recruits AMAP1; and AMAP1 then binds to the mesenchymal-specific protein EPB41L5, which promotes epithelial-mesenchymal transition and focal adhesion dynamics. In renal cancer cells, lysophosphatidic acid (LPA) activates Arf6 via its G-protein-coupled receptors, in which GTP-Gα12 binds to EFA6. The Arf6-based pathway may also contribute to drug resistance. Our results identify a specific mesenchymal molecular machinery of primary ccRCCs, which is triggered by a product of autotaxin and it is associated with poor outcome of patients.

UR - http://www.scopus.com/inward/record.url?scp=84957573832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957573832&partnerID=8YFLogxK

U2 - 10.1038/ncomms10656

DO - 10.1038/ncomms10656

M3 - Article

C2 - 26854204

AN - SCOPUS:84957573832

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10656

ER -